Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Not everyone responds to statins, the standard treatment for people at risk of cardiovascular disease, so an alternative ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

The heart drug digoxin could potentially be combined with existing cancer therapies to prevent the spread of tumors, an early ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.